Literature DB >> 8342973

[The usefulness of computerized axial tomography (CT) in establishing the composition of calculi].

F J Burgos1, J Sánchez, S Avila, J C Saez, A Escudero Barrilero.   

Abstract

Determining stone composition before extracorporeal lithotripsy can be potentially useful. A total of 90 calculi of 6 different chemical composition (calcium oxalate monohydrate, calcium oxalate dihydrate, magnesium ammonium phosphate, phosphate carbonate, uric acid and phosphate oxalate) were analyzed in vitro using computed tomography (CT). The mean, central, peripheral, maximum, minimum stone density and stone morphology were determined. At least in vitro, the serial analyses of the mean, minimum, central stone density and stone morphology permitted distinguishing these 6 types of calculi, although 53% of the calcium oxalate dihydrate calculi could not be distinguished from the phosphate oxalate stones.

Entities:  

Mesh:

Year:  1993        PMID: 8342973

Source DB:  PubMed          Journal:  Arch Esp Urol        ISSN: 0004-0614            Impact factor:   0.436


  3 in total

1.  Using Helical CT to Predict Stone Fragility in Shock Wave Lithotripsy (SWL).

Authors:  James C Williams; Chad A Zarse; Molly E Jackson; James E Lingeman; James A McAteer
Journal:  AIP Conf Proc       Date:  2007-04-05

Review 2.  Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline.

Authors:  M Straub; W L Strohmaier; W Berg; B Beck; B Hoppe; N Laube; S Lahme; M Schmidt; A Hesse; K U Koehrmann
Journal:  World J Urol       Date:  2005-11-29       Impact factor: 4.226

3.  Helical CT evaluation of the chemical composition of urinary tract calculi with a discriminant analysis of CT-attenuation values and density.

Authors:  Marie-France Bellin; Raphaëlle Renard-Penna; Pierre Conort; Anne Bissery; Jean-Baptiste Meric; Michel Daudon; Alain Mallet; François Richard; Philippe Grenier
Journal:  Eur Radiol       Date:  2004-06-25       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.